Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or in...

por Simões, Belinda Pinto, Braga Junior, José Wilson Ramos, Rego, Maria Aparecida do Carmo, de Souza, Cármino Antônio
Publicado 2011

Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia

por Conchon, Monika, Freitas, Carla Maria Boquimpani de Moura, Rego, Maria Aparecida do Carmo, Braga Junior, José Wilson Ramos
Publicado 2011